Vancouver, British Columbia – (PR Newswire) – Thursday, May 16, 2019 – StillCanna Inc. (CSE: STIL) ("STIL" or the "Company") is pleased to announce that Dr. Brian Martin, ND has joined the StillCanna Team. Dr. Martin brings a wealth of knowledge and experience, including but not limited to:
Dr. Martin will lead the Company’s consumer and Nutraceutical and Cosmeceutical product formulations with the goal of enhancing the natural capabilities of CBD and other therapeutic cannabinoids, including terpenes and other organic compounds. He will be the Company’s medical representative for industry research, speaking engagements and product formulations. Dr. Martin will evaluate the current Olimax product line and expects to formulate new CBD related products with a special focus on the expanding nutritional (food and beverages) and wellness marketplaces. Particular attention will be directed towards the female market, along with matters related to the improvement of quality of life, including products aiming to enhance energy, mood, memory, libido and athletic performance.
“Dr. Martin has dedicated his life to the proactive empowerment of the modern consumer, and has developed substantial practical experience and knowledge of the current health needs of both men and women” exclaimed Jason Dussault Chief Executive Officer of StillCanna. “We anticipate that his practical knowledge and capabilities will make StillCanna’s CBD products increasingly effective and metabolically friendly compared to other products currently available in the market. Dr. Martin will work with the Company part time for the next 2 quarters with an eye towards full time employment as we expand our product vision.”
“I have been very impressed with some of the proprietary techniques and technologies StillCanna has relating to the production and formulation of various CBD products,” stated Dr. Martin. “StillCanna’s vision of CBD in the wellness and the global Nutraceutical market is in line with the types of CBD products I envision. StillCanna’s CEO has strong branding and marketing skills which, coupled with my formulation skills, paints a very exciting picture.”
As partial compensation for the engagement of Dr. Martin, the Company will grant 200,000 incentive stock options to Dr. Martin with an exercise price equivalent to a 5% premium to the closing price of the Company’s common shares on the date of grant.
Further to its press release dated May 7, 2019, the Company has also issued 850,000 common shares to certain finders in connection with the acquisition of Olimax. As a result, an aggregate of 1,300,000 common shares have been issued to finders in connection with the acquisition of Olimax.
Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the enhancement of the natural capabilities of CBD and other therapeutic cannabinoids, the formulation of new CBD related products, including products to enhance energy, mood, memory, libido and athletic performance, the increased effectiveness and metabolic friendliness of the Company’s products and the hiring of Dr. Martin as a full time employee of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should" or "would" occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the Company will be able to enhance the natural capabilities of CBD and other therapeutic cannabinoids, that the Company will be able to formulate new CBD related products, including products to enhance energy, mood, memory, libido and athletic performance, that the Company will be able to increase the effectiveness and metabolic friendliness of the its products and that the Company will be able to hire Dr. Martin as a full time employee of the Company. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, that the Company will not be able to enhance the natural capabilities of CBD and other therapeutic cannabinoids, that the Company will not be able to formulate new CBD related products, including products to enhance energy, mood, memory, libido and athletic performance, that the Company will not be able to increase the effectiveness and metabolic friendliness of the its products and that the Company will not be able to hire Dr. Martin as a full time employee of the Company. Readers are cautioned not to place undue reliance on forward-looking statements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.